ORIC vs. ACAD, VCEL, ZLAB, MLTX, MOR, BHC, MRUS, RXRX, AMRX, and CPRX
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Zai Lab (ZLAB), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Bausch Health Companies (BHC), Merus (MRUS), Recursion Pharmaceuticals (RXRX), Amneal Pharmaceuticals (AMRX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
ORIC Pharmaceuticals vs.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
ACADIA Pharmaceuticals currently has a consensus target price of $25.25, indicating a potential upside of 34.95%. ORIC Pharmaceuticals has a consensus target price of $18.29, indicating a potential upside of 64.88%. Given ORIC Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals received 828 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 73.03% of users gave ORIC Pharmaceuticals an outperform vote.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to ORIC Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat ORIC Pharmaceuticals' return on equity.
ACADIA Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 5 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.96 beat ACADIA Pharmaceuticals' score of 0.89 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media.
ACADIA Pharmaceuticals has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ACADIA Pharmaceuticals beats ORIC Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ORIC) was last updated on 1/30/2025 by MarketBeat.com Staff
